IL126548A - תכשירי רוקחות המדכאים את מערכת החיסון המכילים אספירוכלורין או תולדת ה--9 דהכלור שלו - Google Patents
תכשירי רוקחות המדכאים את מערכת החיסון המכילים אספירוכלורין או תולדת ה--9 דהכלור שלוInfo
- Publication number
- IL126548A IL126548A IL12654897A IL12654897A IL126548A IL 126548 A IL126548 A IL 126548A IL 12654897 A IL12654897 A IL 12654897A IL 12654897 A IL12654897 A IL 12654897A IL 126548 A IL126548 A IL 126548A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- cells
- formula
- useful
- immunosuppressive
- Prior art date
Links
- 230000001506 immunosuppresive effect Effects 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 20
- HEXYWHYANGOMLJ-UHFFFAOYSA-N Aspirochlorine Natural products COC1c2cc(Cl)c(O)cc2OC13N4SSC(NC3=O)C4=O HEXYWHYANGOMLJ-UHFFFAOYSA-N 0.000 title description 25
- XMFSSFONDVHNFO-AUTRQRHGSA-N Aspirochlorine Chemical compound N1C(=O)[C@]23OC4=CC(O)=C(Cl)C=C4[C@@H]3SS[C@H]1C(=O)N2OC XMFSSFONDVHNFO-AUTRQRHGSA-N 0.000 title description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 239000000460 chlorine Chemical group 0.000 claims abstract description 7
- 229910052801 chlorine Chemical group 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 20
- 208000023275 Autoimmune disease Diseases 0.000 claims description 18
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 8
- 230000024932 T cell mediated immunity Effects 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 description 40
- 210000001744 T-lymphocyte Anatomy 0.000 description 36
- 239000000427 antigen Substances 0.000 description 36
- 102000036639 antigens Human genes 0.000 description 36
- 108091007433 antigens Proteins 0.000 description 36
- 201000010099 disease Diseases 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 32
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 26
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 26
- 230000028993 immune response Effects 0.000 description 26
- 230000007246 mechanism Effects 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 210000000987 immune system Anatomy 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 108010062580 Concanavalin A Proteins 0.000 description 14
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 230000000735 allogeneic effect Effects 0.000 description 14
- 230000021633 leukocyte mediated immunity Effects 0.000 description 14
- 210000000056 organ Anatomy 0.000 description 14
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 12
- 230000009471 action Effects 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 230000001629 suppression Effects 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 230000003044 adaptive effect Effects 0.000 description 8
- 230000000843 anti-fungal effect Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000000470 constituent Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000033289 adaptive immune response Effects 0.000 description 6
- NVCJFEMWTAVKAU-KWHPKRGUSA-N antibiotic a 30641 Chemical compound S1S[C@H]2C3=CC(Cl)=C(O)C=C3OC22C(=O)N(OC)[C@@H]1C(=O)N2 NVCJFEMWTAVKAU-KWHPKRGUSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000004154 complement system Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 229940125721 immunosuppressive agent Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000000066 myeloid cell Anatomy 0.000 description 6
- 201000003068 rheumatic fever Diseases 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000000224 granular leucocyte Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- -1 PrimogelTM Polymers 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000004721 adaptive immunity Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- 241000134719 Aspergillus tamarii Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000008649 adaptation response Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 244000000054 animal parasite Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000007233 immunological mechanism Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 2
- 229940012189 methyl orange Drugs 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000004719 natural immunity Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000012056 semi-solid material Substances 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96106991 | 1996-05-03 | ||
| PCT/EP1997/002049 WO1997041862A1 (en) | 1996-05-03 | 1997-04-23 | Use of aspirochlorine or derivatives thereof as immunosuppressive agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL126548A0 IL126548A0 (en) | 1999-08-17 |
| IL126548A true IL126548A (he) | 2002-02-10 |
Family
ID=8222742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12654897A IL126548A (he) | 1996-05-03 | 1997-04-23 | תכשירי רוקחות המדכאים את מערכת החיסון המכילים אספירוכלורין או תולדת ה--9 דהכלור שלו |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6133254A (he) |
| EP (1) | EP0914129B1 (he) |
| JP (1) | JP4287908B2 (he) |
| KR (1) | KR100439928B1 (he) |
| AT (1) | ATE209493T1 (he) |
| AU (1) | AU705290B2 (he) |
| CA (1) | CA2253635C (he) |
| DE (1) | DE69708645T2 (he) |
| DK (1) | DK0914129T3 (he) |
| ES (1) | ES2163763T3 (he) |
| IL (1) | IL126548A (he) |
| PT (1) | PT914129E (he) |
| WO (1) | WO1997041862A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007287928A (ja) | 2006-04-17 | 2007-11-01 | Nec Electronics Corp | 半導体集積回路およびその製造方法ならびにマスク |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001086A (en) * | 1975-07-18 | 1977-01-04 | Eli Lilly And Company | Antibiotic a-30641 and process for production thereof |
| US3991052A (en) * | 1975-07-18 | 1976-11-09 | Eli Lilly And Company | Antibiotic A-30641 |
| JP3383718B2 (ja) * | 1995-02-15 | 2003-03-04 | ニチモウ株式会社 | 大豆蛋白を原料とした生成物の製造方法 |
-
1997
- 1997-04-23 KR KR10-1998-0708829A patent/KR100439928B1/ko not_active Expired - Lifetime
- 1997-04-23 DE DE69708645T patent/DE69708645T2/de not_active Expired - Lifetime
- 1997-04-23 ES ES97921706T patent/ES2163763T3/es not_active Expired - Lifetime
- 1997-04-23 AT AT97921706T patent/ATE209493T1/de active
- 1997-04-23 JP JP53947397A patent/JP4287908B2/ja not_active Expired - Lifetime
- 1997-04-23 IL IL12654897A patent/IL126548A/he not_active IP Right Cessation
- 1997-04-23 AU AU27684/97A patent/AU705290B2/en not_active Expired
- 1997-04-23 US US09/171,848 patent/US6133254A/en not_active Expired - Lifetime
- 1997-04-23 DK DK97921706T patent/DK0914129T3/da active
- 1997-04-23 PT PT97921706T patent/PT914129E/pt unknown
- 1997-04-23 WO PCT/EP1997/002049 patent/WO1997041862A1/en not_active Ceased
- 1997-04-23 EP EP97921706A patent/EP0914129B1/en not_active Expired - Lifetime
- 1997-04-23 CA CA002253635A patent/CA2253635C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0914129B1 (en) | 2001-11-28 |
| CA2253635A1 (en) | 1997-11-13 |
| US6133254A (en) | 2000-10-17 |
| DE69708645T2 (de) | 2002-08-08 |
| PT914129E (pt) | 2002-04-29 |
| WO1997041862A1 (en) | 1997-11-13 |
| DE69708645D1 (de) | 2002-01-10 |
| JP2000514403A (ja) | 2000-10-31 |
| AU705290B2 (en) | 1999-05-20 |
| ATE209493T1 (de) | 2001-12-15 |
| DK0914129T3 (da) | 2002-01-28 |
| ES2163763T3 (es) | 2002-02-01 |
| JP4287908B2 (ja) | 2009-07-01 |
| KR100439928B1 (ko) | 2004-12-16 |
| KR20000010724A (ko) | 2000-02-25 |
| IL126548A0 (en) | 1999-08-17 |
| CA2253635C (en) | 2006-01-03 |
| EP0914129A1 (en) | 1999-05-12 |
| AU2768497A (en) | 1997-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sullivan | Graft-vs-host disease | |
| US20090054358A1 (en) | Flt3 inhibitors for immune suppression | |
| JP2005517637A (ja) | 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法 | |
| FI102755B (fi) | Menetelmä uuden, terapeuttisesti käyttökelpoisen yhdisteen tai sen suo lan valmistamiseksi | |
| Minagawa et al. | Experimental allergic encephalomyelitis in the Lewis rat: a model of predictable relapse by cyclophosphamide | |
| US6133254A (en) | Use of aspirochlorine or derivatives thereof as immunosuppressive agents | |
| Wyler et al. | Macrophage activation for antileishmanial defense by an apparently novel mechanism. | |
| Finelli et al. | Recurrent aseptic meningitis in an elderly man: unusual prodrome of systemic lupus erythematosus | |
| Chen et al. | Chronically HIV-1-infected monocytic cells induce apoptosis in cocultured T cells | |
| CA2044328A1 (en) | Efomycins a.e. and g as antiinflammatory agents | |
| Bell et al. | Characterization of a cell population in thoracic duct lymph that adoptively transfers rejection of adult Trichinella spiralis to normal rats | |
| SA109300384B1 (ar) | مشتقات 5-(4- ميثان سلفونيل-فينيل)- ثيازول لعلاج الأمراض الالتهابية الحادة والمزمنة | |
| NO305207B1 (no) | Nye trans-syklopentanylpurinanaloger som er anvendbare som immunoundertrykkende midler | |
| ARONSON | Septicemia from Concomitant Infection with Trypanosoma Cruzi and Neisseria Perflava: First Case of Laboratory-acquired Chagas' Disease in the United States | |
| US5453431A (en) | Use of hydroxychloroquine for treatment of graft-versus-host disease | |
| AU642526B2 (en) | Method of immunosuppression using cyclopentenyl substituted nucleoside analogs and compositions thereof | |
| KR102316961B1 (ko) | 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물 | |
| Crow | Enhancement of the impaired autologous mixed leukocyte reaction in patients with systemic lupus erythematosus. | |
| JP3817273B2 (ja) | 免疫抑制治療、抗ガン治療および抗ウイルス治療用の薬学的組成物 | |
| US5962511A (en) | Drugs for allergic and eosinophilic diseases | |
| Marcus et al. | In vitro studies in reproductive immunology, 3. Restoration of mitogenic activity of lymphocytes inhibited by seminal plasma in man | |
| CN120241739A (zh) | Menin抑制剂BN104在制备预防和治疗移植物抗宿主病的应用 | |
| EP0472181A2 (en) | 5-Amine substituted adenosine analogs as immunosuppressants | |
| 小濱靖弘 et al. | Studies on thermophile products. V. Immunosuppressive profile in vitro of Bacillus stearothermophilus component, Fr. 5-B. | |
| House et al. | An in vitro study of renal allograft recipients for cellular delayed type hypersensitivity to glomerular basement membrane and disrupted spleen cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |